Partner With Us
The C5Research team is comprised of experienced and dedicated physicians, nurses, technologists and support staff within the Heart, Vascular and Thoracic Institute of Cleveland Clinic providing academic leadership and coordination for trials ranging in size from less than 50 to more than 24,000 patients.
- We will provide you with real world clinical expertise to deliver integrity and credibility to all aspects of clinical trial conduct.
- We bring scientific and clinical leadership in cardiovascular disease and other specialties in combination with operational excellence to conduct Phase I-IV multicenter clinical trials.
Cleveland Clinic is nationally ranked and globally recognized as the world leader in cardiovascular care.
Learn MoreServices
Learn more about the services we offer including cardiovascular imaging, our clinical events committee, as well as other support services.
Trial Results
View recently completed clinical trials at Cleveland Clinic, as well as their results.
Podcasts
ACC Late Breaking Science: TACTiC Trial
Dr. Nissen worked with C5Research to investigate if a technology-assisted web application can help consumers appropriately determine if they qualify for a statin drug without a prescription.
Diversity in Clinical Trials: Understanding Common Perceptions
Age, gender, weight, race, ethnicity, and other factors affect how different individuals react to the same treatment. It is important that there is equity in in clinical trials. Ashish Sarraju, MD, speaks with Jenn Mitchell, RN, about the importance of a diverse and equitable participant group.
Lorundrostat: Results from Advance-HTN Phase 2 Study
Luke Laffin, MD, shares the findings from a late breaker he presented at ACC 2025. Lorundrostat is an investigational drug found to significantly lower 24-hour blood pressure among patients with uncontrolled and resistant hypertension.
Cardiac Imaging in the VALOR-HCM Trial
Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
